{"doi":"10.1016/j.jacc.2026.03.026","title":"Interchangeability of the KCCQ-12 and KCCQ-23 Across &gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure","abstract":null,"journal":"JACC","year":2026,"id":637588,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1655603,"name":"Brian L. Claggett","orcid":null,"position":1,"is_corresponding":false},{"id":57261,"name":"Akshay S. Desai","orcid":"0000-0002-1443-0701","position":2,"is_corresponding":false},{"id":290057,"name":"Eldrin F. Lewis","orcid":null,"position":3,"is_corresponding":false},{"id":57280,"name":"Pardeep S. Jhund","orcid":"0000-0003-4306-5317","position":4,"is_corresponding":false},{"id":49640,"name":"Carolyn S.P. Lam","orcid":"0000-0003-1903-0018","position":5,"is_corresponding":false},{"id":57256,"name":"Felipe A. Martinez","orcid":null,"position":6,"is_corresponding":false},{"id":2633,"name":"Faı̈ez Zannad","orcid":"0000-0001-7456-1570","position":7,"is_corresponding":false},{"id":39751,"name":"Marc A. Pfeffer","orcid":"0000-0003-3876-7568","position":8,"is_corresponding":false},{"id":2612,"name":"John J.V. McMurray","orcid":"0000-0002-6317-3975","position":9,"is_corresponding":false},{"id":27970,"name":"Scott D. Solomon","orcid":"0000-0003-3698-9597","position":10,"is_corresponding":false},{"id":61406,"name":"Muthiah Vaduganathan","orcid":"0000-0003-0885-1953","position":11,"is_corresponding":false},{"id":1647626,"name":"Yasuhiro Hamatani","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Interchangeability of the KCCQ-12 and KCCQ-23 Across &gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure","abstract":"BACKGROUND: The 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) is formally qualified by the Food and Drug Administration as a valid patient-reported outcome measure for use in heart failure (HF) clinical trials. However, its length may increase respondent burden. The 12-item version (KCCQ-12) provides a more efficient alternative but was originally developed and validated in HF with reduced left ventricular ejection fraction (LVEF), and its performance relative to the KCCQ-23 has not been evaluated in HF with mildly reduced or preserved LVEF (HFmrEF/HFpEF). OBJECTIVE: The purpose of this study is to examine the interchangeability of KCCQ-12 and KCCQ-23 in patients with HFmrEF/HFpEF. METHODS: We conducted a participant-level pooled analysis of 4 randomized clinical trials (TOPCAT, PARAGON-HF, DELIVER, and FINEARTS-HF), including adults with HFmrEF/HFpEF. All trials collected the KCCQ-23 at baseline and follow-up visits. In this study, the KCCQ-12 overall summary scores (OSS) were derived from individual items of the KCCQ-23 OSS. Both scores ranged from 0 (worst) to 100 (best). We assessed concordance between KCCQ-12 OSS and KCCQ-23 OSS and compared prognostic discrimination and treatment-related changes. RESULTS: Of 18,216 participants (mean age: 72 ± 9 years; female: 46%; NYHA functional class II: 72%; mean LVEF: 55 ± 8%; median N-terminal pro-B-type natriuretic peptide levels: 987 [IQR: 517-1,781] pg/mL), baseline KCCQ-23 OSS was 65.5 ± 21.4, and KCCQ-12 OSS was 64.1 ± 21.7. Baseline KCCQ-12 OSS strongly correlated with KCCQ-23 OSS (Spearman ρ = 0.987), consistent across major subgroups and follow-up visits (all Spearman ρ > 0.980). Prognostic discrimination for cardiovascular death and HF hospitalization was comparable (C index: 0.583 for KCCQ-23 vs 0.586 for KCCQ-12). Treatment effects of HF drugs on KCCQ-OSS were similar across the 2 instruments in each trial and at each time point (all the differences between KCCQ-23 and KCCQ-12 were <1 point on a 0-100 scale). CONCLUSIONS: In patients with HFmrEF/HFpEF, the KCCQ-12 closely parallels the KCCQ-23, demonstrating comparable prognostic performance and treatment responsiveness. These findings support the KCCQ-12 as a lower-burden alternative for use in HF clinical trials. (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; NCT00094302; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin Receptor Blocker Global Outcomes in HF with Preserved Ejection Fraction; NCT01920711; Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure; NCT03619213; Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure; NCT04435626).","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41995644","pmcid":null,"openalex_id":"https://openalex.org/W7137382170","authors":[],"funders":[{"funder_name":"Bayer AG","grant_id":"","title":null},{"funder_name":"U.S. Food and Drug Administration","grant_id":"","title":null}],"total_grants":2,"fwci":7.9352,"citation_percentile":0.95527649,"influential_citations":0,"citation_trend":[{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.jacc.2026.03.026","host_type":"journal"},{"url":"https://doi.org/10.1016/j.jacc.2026.03.026","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S073510972605744X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S073510972605744X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41995644","host_type":"repository"},{"url":"https://hal.univ-lorraine.fr/hal-05600647","host_type":"repository"}],"fields_of_study":["Heart Failure Treatment and Management","Cardiovascular Function and Risk Factors","Cardiac pacing and defibrillation studies","Humans","Heart Failure","Female","Stroke Volume","Aged","Male","Randomized Controlled Trials as Topic","Patient Reported Outcome Measures","Middle Aged","Surveys and Questionnaires"],"mesh_terms":["Patient Reported Outcome Measures","Aged","Female","Heart Failure","Humans","Male","Middle Aged","Surveys and Questionnaires","Stroke Volume","Randomized Controlled Trials as Topic"],"keywords":["Interchangeability","Heart failure","Ejection fraction","Respondent","Food and drug administration","Clinical trial","Quality of life","Health Status","Kansas City Cardiomyopathy Questionnaire"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T19:11:58.858141Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}